4D Molecular Therapeutics, Inc. (FDMT): who owns it and who trades it
As of Nov 16, 2026, FDMT insiders reported 25 open-market sales worth $5.4M and no purchases in the last 12 months, with 14% of the sale value made under pre-set 10b5-1 plans. The largest seller was David Kirn (Director), with $5M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling 4D Molecular Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns FDMT
157 funds and institutions reported FDMT shares worth $777M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Jupiter Topco LLC with 11.5%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Jupiter Topco LLC | 5.75M | 11.54% | $76.5M | – |
| Ra Capital Management, L.P. | 5.05M | 10.14% | $67.2M | No change |
| BlackRock, Inc. | 4.55M | 9.13% | $60.5M | +10% |
| Goldman Sachs Group Inc | 4.26M | 8.56% | $56.6M | +1% |
| Novo Holdings A/s | 3.25M | 6.53% | $43.2M | -11% |
| State Street Corp | 2.91M | 5.85% | $38.7M | +8% |
| Bvf Inc | 2.88M | 5.78% | $38.3M | No change |
| T. Rowe Price Investment Management, Inc. | 2.51M | 5.05% | $33.4M | – |
| Adage Capital Partners Gp, L.l.c. | 2.25M | 4.52% | $29.9M | +40% |
| Trails Edge Capital Partners, LP | 2.23M | 4.48% | $29.6M | +71% |
| Vanguard Capital Management LLC | 2.10M | 4.22% | $27.9M | -4% |
| Armistice Capital, LLC | 2.00M | 4.02% | $26.6M | No change |
| Geode Capital Management, LLC | 1.13M | 2.27% | $15M | +6% |
| Bank of America Corp | 1.12M | 2.25% | $14.9M | +15% |
| Evergreen Quality Fund GP, Ltd. | 951,474 | 1.91% | $12.7M | No change |
| Parkman Healthcare Partners LLC | 948,184 | 1.90% | $12.6M | +81% |
| Dimensional Fund Advisors LP | 730,857 | 1.47% | $9.7M | +40% |
| Deutsche Bank Ag\ | 710,942 | 1.43% | $9.5M | +0% |
| Citadel Advisors LLC | 687,597 | 1.38% | $9.1M | +160% |
| Renaissance Technologies LLC | 614,573 | 1.23% | $8.2M | +6% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, FDMT insiders reported $0 of open-market purchases and $5.4M of sales. 14% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Scott Bizily | Chief Legal Officer | Sale plan | 1,635 | $12.84 | $21K | Form 4 |
| Oct 5, 2026 | David Kirn | Director | Sale plan | 58,061 | $12.92 | $750K | Form 4 |
| Oct 5, 2026 | David Kirn | Director | Sale plan | 272 | $13.61 | $3.7K | Form 4 |
| Sep 16, 2026 | Scott Bizily | Chief Legal Officer | Sale | 1,635 | $13.65 | $22.3K | Form 4 |
| Sep 14, 2026 | David Kirn | Director | Sale | 58,333 | $13.90 | $811K | Form 4 |
| Sep 1, 2026 | Scott Bizily | Chief Legal Officer | Sale | 584 | $14.00 | $8.2K | Form 4 |
| Aug 19, 2026 | David Kirn | Director | Sale | 43,149 | $15.36 | $663K | Form 4 |
| Aug 19, 2026 | David Kirn | Director | Sale | 25,927 | $16.42 | $426K | Form 4 |
| Aug 17, 2026 | Scott Bizily | Chief Legal Officer | Sale | 1,635 | $12.20 | $19.9K | Form 4 |
| Aug 13, 2026 | Scott Bizily | Chief Legal Officer | Sale | 1,635 | $12.00 | $19.6K | Form 4 |
| Aug 4, 2026 | David Kirn | Director | Sale | 26,842 | $10.23 | $275K | Form 4 |
| Aug 3, 2026 | David Kirn | Director | Sale | 12,415 | $10.05 | $125K | Form 4 |
| Jul 10, 2026 | David Kirn | Director | Sale | 15,283 | $12.01 | $184K | Form 4 |
| Jul 10, 2026 | David Kirn | Director | Sale | 442 | $12.84 | $5.7K | Form 4 |
| Jul 9, 2026 | David Kirn | Director | Sale | 42,608 | $12.87 | $548K | Form 4 |
| Jun 30, 2026 | Scott Bizily | Chief Legal Officer | Sale | 6,566 | $14.00 | $91.9K | Form 4 |
| Jun 23, 2026 | Scott Bizily | Chief Legal Officer | Sale | 9,810 | $12.00 | $118K | Form 4 |
| Jun 22, 2026 | David Kirn | Director | Sale | 114,746 | $10.47 | $1.2M | Form 4 |
| Jun 1, 2026 | David Kirn | Director | Sale | 1,922 | $10.02 | $19.3K | Form 4 |
| Mar 20, 2026 | Ashoo Gupta | Vice president | Sale | 310 | $8.61 | $2.7K | Form 4 |
| Mar 20, 2026 | Ashoo Gupta | Vice president | Sale | 80 | $8.61 | $689 | Form 4 |
| Dec 20, 2025 | Ashoo Gupta | Vice president | Sale | 310 | $8.68 | $2.7K | Form 4 |
| Dec 20, 2025 | Ashoo Gupta | Vice president | Sale | 79 | $8.68 | $686 | Form 4 |
| Dec 16, 2025 | Scott Bizily | Chief Legal Officer | Sale | 1,635 | $10.90 | $17.8K | Form 4 |
| Nov 17, 2025 | Scott Bizily | Chief Legal Officer | Sale | 1,635 | $10.59 | $17.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| David Kirn | See Remarks, Director | – | $5M | Oct 5, 2026 |
| Scott Bizily | Chief Legal Officer | – | $336K | Oct 16, 2026 |
| Ashoo Gupta | VP, Finance and Controller | – | $6.7K | Mar 20, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
FDMT short interest
10.90M FDMT shares are sold short. Over the last 12 reports the number of shares short went down 10%.
As of Oct 30, 2026, 10.90M FDMT shares were sold short, down 5.5% from the report before. At the average daily volume of 1.05M shares, buying them all back would take about 10.4 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.90M | – | -5% | 1.05M | 10.4 |
| Oct 15, 2026 | 11.53M | – | +3% | 960,955 | 12.0 |
| Sep 30, 2026 | 11.24M | – | -6% | 1.20M | 9.3 |
| Sep 15, 2026 | 12.01M | – | -1% | 647,409 | 18.6 |
| Aug 31, 2026 | 12.07M | – | -2% | 1.48M | 8.2 |
| Aug 14, 2026 | 12.29M | – | +2% | 550,714 | 22.3 |
| Jul 31, 2026 | 12.04M | – | +6% | 680,478 | 17.7 |
| Jul 15, 2026 | 11.36M | – | -15% | 732,623 | 15.5 |
| Jun 30, 2026 | 13.31M | – | +3% | 1.46M | 9.1 |
| Jun 15, 2026 | 12.93M | – | +6% | 782,378 | 16.5 |
| May 29, 2026 | 12.19M | – | +1% | 872,663 | 14.0 |
| May 15, 2026 | 12.08M | – | +1% | 633,230 | 19.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
4D Molecular Therapeutics company events
4D Molecular Therapeutics filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Sep 28, 2026.
- Sep 28, 2026Announcement4D Molecular Therapeutics, Inc. reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 20, 2026Announcement4D Molecular Therapeutics, Inc. reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration population. 2-Year Data from PRISM Phase 2b Clinical Trial (Data Cutoff May 18, 2026): Trial and Patient Cohort Overview • The Phase… Filing
- Jun 29, 2026Agreement4D Molecular Therapeutics, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc., providing for term loans in an of up to $200.0 million, subject to the terms and conditions set forth therein. Filing
- Jun 22, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 30, 2026LeadershipThe Board of Directors of 4D Molecular Therapeutics, Inc. appointed Kristian Humer as the Company’s Principal Accounting Officer, effective immediately. Filing
- Mar 18, 2026ResultsReleased financial results. Filing
- Jan 26, 2026SharesSold new shares outside a public offering. Filing
- Jan 7, 2026LeadershipIn connection with his transition to a new part-time employment position, Fariborz Kamal, Ph.D., resigned as President and Chief Operating Officer of the Company effective immediately to pursue other opportunities. Filing
- Dec 10, 2025Announcement4D Molecular Therapeutics, Inc. announced its intention to implement protocol amendments to the 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials of 4D-150 in wet AMD to increase target enrollment from 400 to 480 patients per trial. Filing
- Nov 17, 2025LeadershipKristian Humer joined 4D Molecular Therapeutics, Inc. as Chief Financial Officer and Principal Financial Officer. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
4D Molecular Therapeutics financials
Famous investors that hold FDMT
4 of the 50 well-known investors we track reported holding FDMT in their latest 13F filing. The largest position is Jim Simons's, worth $5.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 411,786 | $5.9M | 0.0% | -33% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 154,311 | $2.2M | 0.0% | -78% |
| Israel Englander · Millennium Management | Q3 2026 | 136,373 | $2M | 0.0% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 58,546 | $838K | 0.0% | -11% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named FDMT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 7.3% |
| Nov 16, 2026 | Novo Holdings A/S | 13G/A | 5.4% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 7.3% |
| Nov 16, 2026 | Novo Holdings A/S | 13G/A | 5.4% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.5% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.5% |
Questions about 4D Molecular Therapeutics, Inc. (FDMT) stock
Who owns the most FDMT stock?
The largest reported owner of 4D Molecular Therapeutics, Inc. (FDMT) is Jupiter Topco LLC, with 11.5% of the company. In total, 157 funds and institutions reported holding FDMT at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are FDMT insiders buying or selling?
In the last 12 months, FDMT insiders reported no open-market purchases and 25 sales worth $5.4M. The latest trade was on Oct 16, 2026. See every trade.
What is the short interest in FDMT?
As of Oct 30, 2026, 10.90M FDMT shares were sold short, down 5.5% from the report before. At the average daily volume of 1.05M shares, buying them all back would take about 10.4 trading days (days to cover). See the history.
Which famous investors hold FDMT?
4 of the 50 well-known investors we track reported FDMT in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $5.9M. See all holders.
Executive pay
4D Molecular Therapeutics's chief executive was paid a total of $2.1M for the year ended Dec 31, 2025, up 103% from $1M the year before. In the last 12 months, 4D Molecular Therapeutics's executives and directors bought no stock on the open market and sold $5.4M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.